ADMA Biologics (NASDAQ: ADMA) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare ADMA Biologics to similar companies based on the strength of its institutional ownership, earnings, dividends, risk, valuation, profitability and analyst recommendations.


This table compares ADMA Biologics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ADMA Biologics -35.00% -76.26% -9.77%
ADMA Biologics Competitors -5,310.77% -218.27% -39.48%

Insider and Institutional Ownership

32.8% of ADMA Biologics shares are held by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 60.4% of ADMA Biologics shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares ADMA Biologics and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ADMA Biologics $10.66 million -$19.51 million -3.21
ADMA Biologics Competitors $284.49 million $33.78 million 79.89

ADMA Biologics’ competitors have higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings for ADMA Biologics and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADMA Biologics 0 0 2 0 3.00
ADMA Biologics Competitors 866 3223 11691 232 2.71

ADMA Biologics presently has a consensus price target of $6.50, suggesting a potential upside of 147.15%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.70%. Given ADMA Biologics’ stronger consensus rating and higher possible upside, equities analysts plainly believe ADMA Biologics is more favorable than its competitors.

Risk and Volatility

ADMA Biologics has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500. Comparatively, ADMA Biologics’ competitors have a beta of 6.07, meaning that their average stock price is 507% more volatile than the S&P 500.


ADMA Biologics beats its competitors on 7 of the 12 factors compared.

About ADMA Biologics

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with's FREE daily email newsletter.